Name: Integrin Beta 3 Market Size Share Growth Opportunities and Forecast 2022
Creator: DataM Intelligence
Published: Fri Jan 06 2023 17:44:11 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions
Keywords: integrin beta 3 market, integrin beta 3 market 2029, integrin beta 3 market Industry, integrin beta 3 market share, integrin beta 3 market trends, integrin beta 3 market size, integrin beta 3 market growth, integrin beta 3 market sector, integrin beta 3 market pdf report, integrin beta 3 market analysis, integrin beta 3 market forecast, integrin beta 3 market research, competitive analysis, datam intelligence

Integrin Beta 3 Market Size Share Growth Opportunities and Forecast 2022

Integrin Beta 3 Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Integrin Beta 3 Market is Segmented By Type (MSP-68,&nbsp;OCU-200,&nbsp;AC-301,&nbsp;C-16Y,&nbsp;Others),&nbsp;By Application(Melanoma,&nbsp;Arterial Thrombosis,&nbsp;Diabetic Macular Edema,&nbsp;Cancer, Others),&nbsp;By End-user(Hospital,&nbsp;Clinics,&nbsp;Laboratory,&nbsp;Others),&nbsp;and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

<blockquote>
Integrin Beta 3 Market&nbsp;is&nbsp;expected to reach high at a <a href="https://www.datamintelligence.com/download-sample/integrin-beta-3-market">CAGR</a>&nbsp;during the forecast period (2023-2030).
</blockquote>

Integrins regulate cellular growth, proliferation, migration, signaling, cytokine activation and release and play a key role in cell proliferation and migration, apoptosis, tissue repair, and all other processes involved in inflammation, infection, and angiogenesis. The ITGB3 protein product is the integrin beta chain beta 3, found along with the alpha IIb chain in platelets.

Integrin Beta 3 Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>Integrin Beta 3 Market is expected to reach high at a CAGR during the forecast period (2023-2030).</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Load, By Distribution Channel, By Vehicle and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/integrin-beta-3-market">Click here</a>

<h3>Integrin Beta 3 Market Dynamics</h3>

Integrins regulating stemness in solid tumours is an emerging therapeutic target expected to drive market growth.

Cancer stemness, which relates to cancer cells with a stem cell (SC)-like phenotype, has long been identified as an important factor in carcinogenesis. Cancer stemness increases with tumour growth in general. A tiny population of stem-like cancer cells (i.e., cancer stem cells, CSCs) can self-renew, differentiate, and initiate tumours among the many subsets of cancer cells seen in a tumour. Mounting evidence has established CSCs as drivers of tumour progression, treatment resistance, disease relapse and metastasis. Therefore, Integrin is needed for SCs to sense and respond to various triggers in both normal and sick tissues as a bridge transferring outside-in and inside-out signals. In support of this, more research has revealed that integrins can act as both phenotypic indicators and functional regulators of CSCs, adding to the complexity of CSC regulation and the possibility of developing integrin-targeted treatments to combat cancer stemness. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The developed agent&#39;s activation of integrin signalling is a major drawback of targeting integrin ligand binding, limiting the clinical success of the integrin ligand-based antagonist/agonist. It is one factor that the market is expected to get hampered in the forecast period.

Global Integrin Beta 3 Market - Industry Analysis

<h3>COVID-19 Impact Analysis</h3>

The SARS-CoV-2 pandemic resulted in a near-global lockdown and moderately influenced the integrin beta 3 industry. The SARS-CoV-2 spike protein has been shown to bind multiple integrin subtypes. Although there is growing evidence for interactions based on the spike RGD sequence, the exact binding mechanisms are still unknown. Moreover, computational studies suggest that the spike RGD motif is not completely accessible for integrin-binding. At the same time, there have also been other non-RGD-binding integrins that have been suggested to be potentially involved in SARS-CoV-2 viral entry. The motifs comprise potential binding to RGD-binding integrins, such as &alpha;V&beta;6, as well as non-RGD-binding integrins, such as &alpha;X&beta;2. Additionally, hundreds of relevant clinical trials are currently underway worldwide. Numerous research facilities implemented protocols limiting the number of lab employees allowed on-site to reduce the risk of virus transmission, putting many investigations on hold. Thus, the market will undergo impetus growth during the forecast period.

<h3>Integrin Beta 3 Market Segment Analysis</h3>

Cancer segment is expected to hold the largest market share in integrin beta 3 market.

The cancer segment accounted for the largest market share in 2020. &beta;3 integrin in tumours, the subtype that exhibits the widest range of functions, is &alpha;v&beta;3 integrin. It is associated with the growth, survival, invasion and metastasis of different cancer cells. Moreover, in certain types of cancer, it is an indicator of increased lymph node or bone metastasis and decreased patient survival. Similar to &beta;1 integrin, &beta;3 integrin may also bind with ECM components to form focal adhesions between cancer cells and the ECM. Concomitantly, in suspension, &beta;3 integrin prevents cancer cells from IMD by activating a non-canonical FAK-independent signalling pathway.

Additionally, &beta;3 integrin in endothelial cells can affect the growth of tumours by regulating angiogenesis. Therefore, &beta;3 integrin exhibits the ability to regulate receptor tyrosine kinase (RTK). Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

<h3>Integrin Beta 3 Market Geographical Analysis</h3>

North America region holds the largest market share in the global integrin beta 3 market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of cancer and clinical trials carried out by the market players and well-established healthcare facilities in the region are a few factors due to which the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. In contrast, In 2020, an estimated 1,806,590 new cancer cases were diagnosed in the United States, and 606,520 people died from the disease. The three most common cancers for women are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in 2020. Moreover, Proda Biotech L.L.C. is part of the Drugs and Druggists&#39; Sundries Merchant Wholesalers Industry, located in the U.S.A., has conducted a Phase I study to assess the safety of ProAgio in participants with advanced solid tumour malignancies, including pancreatic cancer. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

<h3>Integrin Beta 3 Market Competitive Landscape</h3>

Major key players in the integrin beta 3 market are GenWay Biotech, Cell Signaling Technology, Inc., Synaptic Systems GmbH, Merck KGaA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , R&amp;D Systems, Inc., Thermo Fisher Scientific Inc., Proteintech Group, Inc., Abcam plc. and Sino Biological Inc.&nbsp;&nbsp;&nbsp;

GenWay Biotech:

Overview:

GenWay Biotech is a well-known developer of protein and antibody solutions. They have offered a broad catalog of goods and services with proteomic solutions and applications to the research community since 1998. GenWay, a protein and antibody solutions provider has a multi-functional technology platform for functional genomics and proteomics that uses genes, proteins, antibodies, and their applications in cells, tissues, and animal models. GenWay&#39;s primary competencies allow them to do bioinformatics analyses on protein targets, manufacture high-quality protein antigens and ligands, and design domain-specific IgY antibodies for immunoaffinity capture, partitioning, detection, and analysis.

Product Portfolio:

Human Integrin Beta3 (Ab-773) Antibody (GWB-ASC722): Integrin beta3 (Ab-773) Antibody detects endogenous levels of total Integrin beta3 protein.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Integrin Beta 3 Market?

Integrin Beta 3 Market is expected to reach high at a CAGR during the forecast period 2023-2030.

Which region controlled the global market during 2023-2030?

North America&nbsp;region Controls&nbsp;the&nbsp;Integrin Beta 3 Market&nbsp;during 2023-2030.

Which is the fastest growing region in the Integrin Beta 3 Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/parathyroid-hormone-market">Parathyroid Hormone Market</a>

<a href="https://www.datamintelligence.com/research-report/twin-neck-dosing-bottle-market">Twin Neck Dosing Bottle Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Application</li>
		<li>Market Snippet by End user</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Integrins regulating stemness in solid tumours is an emerging therapeutic target expected to drive market growth.</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>The developed agent&#39;s activation of integrin signalling is a major drawback of targeting integrin ligand binding, limiting the clinical success of the integrin ligand-based antagonist/agonist. It is one factor that the market is expected to get hampered in the forecast period.</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type Segment</li>
		</ol>
		</li>
		<li>MSP-68*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>OCU-200</li>
		<li>AC-301</li>
		<li>C-16Y</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application Segment</li>
		</ol>
		</li>
		<li>Melanoma*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Arterial Thrombosis</li>
		<li>Diabetic Macular Edema</li>
		<li>Cancer</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By End-user</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user</li>
			<li>Market Attractiveness Index, By End-user Segment</li>
		</ol>
		</li>
		<li>Hospital*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Clinics</li>
		<li>Laboratory</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>List of Key Companies to Watch</li>
		<li>List of Company with disruptive technology</li>
	</ol>
	</li>
	<li>
	<h3>Global Integrin Beta 3 Market- Company Profiles</h3>

	<ol>
		<li>GenWay Biotech*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>&nbsp;Cell Signaling Technology, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Synaptic Systems GmbH</li>
		<li>Merck KGaA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>R&amp;D Systems, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Thermo Fisher Scientific Inc.&nbsp;&nbsp;</li>
		<li>Proteintech Group, Inc.&nbsp;</li>
		<li>Abcam plc.&nbsp;</li>
		<li>Sino Biological Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table1 Global Integrin Beta 3 Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table2 Global Integrin Beta 3 Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)

Table3 Global Integrin Beta 3 Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)

Table4 Global Integrin Beta 3 Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table5 Global Integrin Beta 3 Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table6 Global Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table7 Global Integrin Beta 3 Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)

Table8 Global Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table9 Global Integrin Beta 3 Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)

Table10 Global Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table11 Global Integrin Beta 3 Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table12 Global Integrin Beta 3 Market Value, By Region, 2019-2029 ($ Million)

Table13 North America Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table14 North America Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table15 North America Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table16 North America Integrin Beta 3 Market Value, By Country, 2019-2029 ($ Million)

Table17 South America Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table18 South America Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table19 South America Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table20 South America Integrin Beta 3 Market Value, By Country, 2019-2029 ($ Million)

Table21 Europe Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table22 Europe Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table23 Europe Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table24 Europe Integrin Beta 3 Market Value, By Country, 2019-2029 ($ Million)

Table25 Asia-Pacific Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table26 Asia-Pacific Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table27 Asia-Pacific Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table28 Asia-Pacific Integrin Beta 3 Market Value, By Country, 2019-2029 ($ Million)

Table29 Middle East &amp; Africa Integrin Beta 3 Market Value, By Type, 2019-2029 ($ Million)

Table30 Middle East &amp; Africa Integrin Beta 3 Market Value, By Application, 2019-2029 ($ Million)

Table31 Middle East &amp; Africa Integrin Beta 3 Market Value, By End user, 2019-2029 ($ Million)

Table32 GenWay Biotech: Overview

Table33 GenWay Biotech: Product Portfolio

Table34 GenWay Biotech: Key Developments

Table35 Cell Signaling Technology, Inc.: Overview

Table36 Cell Signaling Technology, Inc.: Product Portfolio

Table37 Cell Signaling Technology, Inc.: Key Developments

Table38 Synaptic Systems GmbH: Overview

Table39 Synaptic Systems GmbH: Product Portfolio

Table40 Synaptic Systems GmbH: Key Developments

Table41 Merck KGaA: Overview

Table42 Merck KGaA: Product Portfolio

Table43 Merck KGaA: Key Developments

Table44 R&amp;D Systems, Inc.: Overview

Table45 R&amp;D Systems, Inc.: Product Portfolio

Table46 R&amp;D Systems, Inc.: Key Developments

Table47 Thermo Fisher Scientific Inc.: Overview

Table48 Thermo Fisher Scientific Inc.: Product Portfolio

Table49 Thermo Fisher Scientific Inc.: Key Developments

Table50 Proteintech Group, Inc.: Overview

Table51 Proteintech Group, Inc.: Product Portfolio

Table52 Proteintech Group, Inc.: Key Developments

Table53 Abcam plc: Overview

Table54 Abcam plc: Product Portfolio

Table55 Abcam plc: Key Developments

Table56 Sino Biological Inc.: Overview

Table57 Sino Biological Inc.: Product Portfolio

Table58 Sino Biological Inc.: Key Developments

List of Figures

Figure1 Global Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure2 Global Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure3 Global Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure4 Global Integrin Beta 3 Market Share, By Region, 2021 &amp; 2029 (%)

Figure5 Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure6 Global Integrin Beta 3 Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure7 MSP-68: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure8 OCU-200: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure9 AC-301: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure10 C-16Y: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure11 Others: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure12 Global Integrin Beta 3 Market Y-o-Y Growth, By Application, 2021-2029 (%)

Figure13 Melanoma: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure14 Arterial Thrombosis: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure15 Diabetic Macular Edema: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure16 Cancer: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure17 Others: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure18 Global Integrin Beta 3 Market Y-o-Y Growth, By End user, 2021-2029 (%)

Figure19 Hospital: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure20 Clinics: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure21 Laboratory: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure22 Others: Global Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure23 Global Integrin Beta 3 Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure24 North America Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure25 North America Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure26 North America Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure27 North America Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure28 North America Integrin Beta 3 Market Share, By Country, 2021 &amp; 2029 (%)

Figure29 South America Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure30 South America Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure31 South America Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure32 South America Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure33 South America Integrin Beta 3 Market Share, By Country, 2021 &amp; 2029 (%)

Figure34 Europe Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure35 Europe Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure36 Europe Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure37 Europe Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure38 Europe Integrin Beta 3 Market Share, By Country, 2021 &amp; 2029 (%)

Figure39 Asia-Pacific Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure40 Asia-Pacific Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure41 Asia-Pacific Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure42 Asia-Pacific Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure43 Asia-Pacific Integrin Beta 3 Market Share, By Country, 2021 &amp; 2029 (%)

Figure44 Middle East &amp; Africa Integrin Beta 3 Market Value, 2019-2029 ($ Million)

Figure45 Middle East &amp; Africa Integrin Beta 3 Market Share, By Type, 2021 &amp; 2029 (%)

Figure46 Middle East &amp; Africa Integrin Beta 3 Market Share, By Application, 2021 &amp; 2029 (%)

Figure47 Middle East &amp; Africa Integrin Beta 3 Market Share, By End user, 2021 &amp; 2029 (%)

Figure48 GenWay Biotech: Financials

Figure49 Cell Signaling Technology, Inc.: Financials

Figure50 Synaptic Systems GmbH: Financials

Figure51 Merck KGaA: Financials

Figure52 R&amp;D Systems, Inc.: Financials

Figure53 Thermo Fisher Scientific Inc.: Financials

Figure54 Proteintech Group, Inc.: Financials

Figure55 Abcam plc: Financials

Figure56 Sino Biological Inc.: Financials